Chronic Kidney Disease
ERA-EDTA offers guidance on selecting patients for treatment, when to start the drug, dosing strategies, and other aspects of care.
Statin users had 30% increased odds of acute kidney injury and 36% increased odds of chronic kidney disease compared with non-users.
Use of oral megestrol acetate (MA) is associate with significant adverse effects.
Chronic kidney disease found to be 58% more likely to develop in individuals with than without the sleep disorder.
New findings suggest the medication induces beneficial renal structural changes.
The drugs do not appear to prevent progression to ESRD, new meta-analysis finds.
Overall albuminuria drop may be too small for cardiovascular, renal risk protection.
Four patients would need to adhere to diet to avoid primary end point in per-protocol analysis.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Serum total and free testosterone declined in men on hemodialysis who received a 6-month course of the drug for secondary hyperparathyroidism.
Treatment corrects anemia and improves quality of life, according to a systemic review.
Less hypoglycemia for patients weighing less than 95 kg, with no impact on potassium lowering.
New risk calculator estimates who will need dialysis in 2 to 5 years.
Renal & Urology News interviewed Matthew R. Weir, MD, director of the division of nephrology and professor of medicine at the University of Maryland School of Medicine in Baltimore.
While study can't prove cause-and-effect, increasing damage seen as dose rises.
Decrease in age-adjusted death rates from 2000 to 2012; increase from 2012 to 2014.
Even mild AKI with rapid recovery is associated with increased risk of chronic kidney disease stage 3 or higher.
2004 to 2012 saw increase in percutaneous ventricular assist devices, intraaortic balloon pump.
In a prospective study, prediabetes was an independent risk factor for hyperfiltration and increased albuminuria.
Even surgery patients with stage 1 AKI without true organ damage had a 43% increase in cardiovascular mortality risk within 10 years compared with patients with no kidney disease.
It has a stronger association with future end-stage renal disease risk than past eGFR decline, large study shows.
Probable interaction described in 5 patients, all of whom had atrial fibrillation.
Direct oral anticoagulants were superior to dose-adjusted warfarin, however, reducing the risk of major bleeding by 19% in patients with mild to moderate renal impairment.
In a study, investigators observed that levels were higher in those with stage 3a than stage 3b chronic kidney disease.
Reduced risk of contrast-induced nephropathy with no increase in acute heart failure.
The death risk decreases 23% with each 33% increase in plant protein to total protein ratio, study finds.
The medication significantly decreased potassium levels over 52 weeks in patients with resistant hypertension and diabetic kidney disease.
Meta-analysis reveals a lower risk of bleeding and arterial thromboembolism compared with conventional agents.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)